Accessibility Menu

Dr. Reddy's Laboratories(FRA) RDDA

Market Cap€8.58BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPON/A
5 YearN/A
1 YearN/A
1 MonthN/A
€10.30
+0.00%
+0.00Today

Dr. Reddy's Laboratories Financials at a Glance

Market Cap

€8.58BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

€3.14K

Net Income (TTM)

€314.65

EPS (TTM)

€0.38

P/E Ratio

26.99

Dividend

€0.07

Beta (Volatility)

0.09 (Low)

Price

€10.30

Volume

0

Open

€10.30

Previous Close

€10.30

Daily Range

€10.30 - €10.30

52-Week Range

€9.85 - €13.30

Estimated Earnings Date

N/A

RDDA News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Dr. Reddy's Laboratories

Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services & Active Ingredients, Proprietary Products, and Others. The Global Generics segment consists of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The Pharmaceutical Services & Active Ingredients segment is comprised of manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API, which are the principal ingredients for finished pharmaceutical products. The Proprietary Products segment focuses on research and development of differentiated formulations. The Others segment includes the operations of the subsidiary of the company. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.

Industry

Pharmaceuticals

Sector

Health Care

Employees

27,811

CEO

Erez Israeli, MBA

Website

www.drreddys.com

RDDA Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

9.07%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

3.71%

Dividend Yield

0.71%

Payout Ratio

N/A

Stock Overview

Market Cap

€8.58BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

832.95M

Volume

0

Avg. Volume

34.409

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Dr. Reddy's Laboratories Performance Analysis

Dr. Reddy's Laboratories annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-03-31EUR 2,941,830,03018.7%
20242024-03-31EUR 3,110,180,2795.7%
20252025-03-31EUR 3,586,538,45215.3%
20262026-03-31EUR 3,281,160,534-8.5%
Dr. Reddy's Laboratories annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-03-31EUR 0.6597.9%
20242024-03-31EUR 0.7414.8%
20252025-03-31EUR 0.750.3%
20262026-03-31EUR 0.50-32.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

€733.03

+0.8%

Gross Profit

€312.97

+0.7%

Gross Margin

42.70%

+0.8%

Market Cap

€8.58BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

€0.39

N/A

Employees

27,811

N/A

Net Income

€39.49

+0.3%

EBITDA

€76.34

+0.3%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

€768.37

+15.5%

Total Debt

€664.85

+1.3%

Accounts Receivable

€929.16

+0.9%

Inventory

€743.58

+1.0%

Long Term Debt

€109.81

+1.3%

Short Term Debt

€555.04

+1.3%

Return on Assets

6.08%

+0.5%

Return on Invested Capital

16.11%

+1.0%

Free Cash Flow

-€41.03

N/A

Operating Cash Flow

-€9.91

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,684.24-0.00%
^DJIDJI
$53,254.61-0.01%
^IXICNASDAQ
$26,319.55-0.00%
BTCBitcoin
$78,890.00-0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About RDDA

What is the current price of Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories is trading at €10.30 per share.

What is the 52-week range for Dr. Reddy's Laboratories?

Over the past 52 weeks, Dr. Reddy's Laboratories has traded between €9.85 and €13.30.

How much debt does Dr. Reddy's Laboratories have?

As of the most recent reporting period, Dr. Reddy's Laboratories reported total debt of €664.85M.

How much cash does Dr. Reddy's Laboratories have on hand?

Dr. Reddy's Laboratories reported €103.53M in cash and cash equivalents in its most recent financial results.

What is Dr. Reddy's Laboratories’s dividend yield?

Dr. Reddy's Laboratories currently has a dividend yield of 0.71%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services